AbbVie secures another Humira settlement
Pavel Kapysh / Shutterstock.com
California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Adamas Pharmaceuticals, Novartis, Sandoz, generics, ANDA, settlement, patent infringement, Gocovri, Parkinson’s